An integrative mendelian randomisation and drug mechanism framework for target prioritisation and therapeutic repurposing in major depression
Authors:
- Abigail R. ter KuileAKAbigail R. ter Kuile
- Chris FinanCFChris Finan
- Sandesh ChopadeSCSandesh Chopade
- Marion van VugtMVMarion van Vugt
- Nikita HukerikarNHNikita Hukerikar
- Serena BarralSBSerena Barral
- Argyris StringarisASArgyris Stringaris
- Amand F. SchmidtASAmand F. Schmidt
- Karoline KuchenbaeckerKKKaroline Kuchenbaecker
- Jean-Baptiste PingaultJPJean-Baptiste Pingault
Open Access
- 2 June 2026
- journal article
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Abstract
Major depression (MD) treatments have limited efficacy and target few mechanisms, highlighting the need for innovative drug discovery. Drugs targeting genetically supported proteins are 2.6 times more likely to succeed in drug development. Here, we use genetic methods to identify and prioritise MD drug targets, leveraging genome-wide association study (GWAS) summary statistics from >525,000 MD cases. We derived exposure data from 10 datasets measuring protein quantitative trait loci (pQTLs) and gene expression levels (eQTLs) in blood, cerebrospinal fluid, and brain tissues. We performed cis -Mendelian randomisation (MR) on 3469 druggable targets (genes encoding proteins targeted by existing compounds or experimentally predicted to be druggable). To strengthen causal inference, we implemented robust MR estimators, colocalisation, external replication, and assessed directional consistency across tissues. We integrated cis -MR effect directions with drug mechanisms and clinical annotations to infer potential therapeutic effects. Validation analyses showed that 82% of drugs approved for depression/anxiety had ≥1 significant MR target, compared to 51% for compounds in clinical trials. For repurposing, we prioritised 54 targets of compounds developed for other conditions with estimated beneficial effects on MD (e.g., an inhibitor for a risk-increasing target). Ten high-priority targets of brain-penetrating compounds included ACE and NISCH (cardiovascular drugs), NDUFA2, NDUFB6, and NDUFS1 (metformin), CDK4, NTRK3, and MET (oncology inhibitors), and GLS and NOS2 (enzyme inhibitors). We found genetic evidence for established and novel MD targets across the drug development pipeline. Novel targets point to mechanisms beyond monoaminergic systems, most with approved drugs for other conditions, offering immediate repurposing opportunities.Keywords
This publication has 100 references indexed in Scilit:
- Effects of the anti-inflammatory pentoxifylline on psychiatric and neuropsychiatric conditions: exploring various off-label utilities with meta-analysesInflammopharmacology, 2025
- Cyclin D1—Cdk4 regulates neuronal activity through phosphorylation of GABAA receptorsCellular and Molecular Life Sciences, 2023
- Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting SystemTargeted Oncology, 2022
- Genetic control of the human brain proteomeThe American Journal of Human Genetics, 2021
- A comparison of robust Mendelian randomization methods using summary dataGenetic Epidemiology, 2020
- Mendelian randomization with fine‐mapped genetic data: Choosing from large numbers of correlated instrumental variablesGenetic Epidemiology, 2017
- Don’t stress about CRF: assessing the translational failures of CRF1antagonistsPsychopharmacology, 2017
- A framework for the investigation of pleiotropy in two‐sample summary data Mendelian randomizationStatistics in Medicine, 2017
- Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median EstimatorGenetic Epidemiology, 2016
- Patterns of linkage disequilibrium in the MHC region on human chromosome 6pHuman Genetics, 2004